Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Crescita Therapeutics Inc T.CTX

Alternate Symbol(s):  CRRTF

Healthcare
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.


TSX:CTX - Post by User

Crescita Therapeutics Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Showmi1on Aug 30, 2017 8:20pm
115 Views
Post# 26639993

Debenture

DebentureSo why the convertable debenture after taking all of that money from the Nuvo group. 
So its gone?

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities